Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 3/2000

Ausgabe 3/2000

Inhaltsverzeichnis ( 11 Artikel )

01.08.2000 | Ausgabe 3/2000

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

Lia van Zuylen, Kees Nooter, Alex Sparreboom, Jaap Verweij

01.08.2000 | Ausgabe 3/2000

Studies on the Cytotoxic, Biochemical and Anti-Carcinogenic Potentials of Ninhydrin on Ehrlich Ascites Carcinoma Cell-Bearing Swiss Albino Mice

S. Qureshi, O.A. Al-Shabanah, A.M. Al-Bekairi, M.M. Al-Harbi, N.M. Al-Gharably, M. Raza

01.08.2000 | Ausgabe 3/2000

The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

Heleen A. Bardelmeijer, Olaf van Tellingen, Jan H.M. Schellens, Jos H. Beijnen

01.08.2000 | Ausgabe 3/2000

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

Yun Oh, Roman Perez-Soler, Frank V. Fossella, Bonnie S. Glisson, Jonathan Kurie, Garrett L. Walsh, Mylene Truong, Dong M. Shin

01.08.2000 | Ausgabe 3/2000

Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma

Paul M. Dodd, John A. McCaffrey, Madhu Mazumdar, Evelyn Icasiano, Geralyn Higgins, Harry Herr, Dean F. Bajorin

01.08.2000 | Ausgabe 3/2000

Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas

T. Chidiac, G.T. Budd, R. Pelley, K. Sandstrom, D. McLain, P. Elson, R. Crownover, K. Marks, G. Muschler, M. Joyce, R. Zehr, R. Bukowski

01.08.2000 | Ausgabe 3/2000

Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer

Thomas Lad, Fred Rosen, David Sciortino, Bruce Brockstein, J. Philip Keubler, Rose Arietta, Everett Vokes

01.08.2000 | Ausgabe 3/2000

Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors

Jacqueline Vuky, John McCaffrey, Michelle Ginsberg, Tania Mariani, Dean F. Bajorin, George J. Bosl, Robert J. Motzer

01.08.2000 | Ausgabe 3/2000

A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413)

John S. Macdonald, Joth L. Jacobson, Manuel Modiano, Dennis F. Moore, David R. Gandara, Louis E. Schroder, Robert A. Chapman

01.08.2000 | Ausgabe 3/2000

A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas

Patrick A. Burch, Albert M. Bernath, Terrence L. Cascino, Bernd W. Scheithauer, Paul Novotny, Suresh Nair, Jan C. Buckner, Delano M. Pfeifle, John W. Kugler, Loren K. Tschetter

01.08.2000 | Ausgabe 3/2000

A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors

Jörg T. Hartmann, Lüder M. Fels, Stefan Knop, Hilmar Stolte, Lothar Kanz, Carsten Bokemeyer

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise